5-Methyl-1,3,4,6-tetrahydrofuro[3,4-c]pyrrole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡咯
• 英文名称: 5-Methyl-1,3,4,6-tetrahydrofuro[3,4-c]pyrrole
• 英文别名: 5-methyl-1,3,4,6-tetrahydrofuro[3,4-c]pyrrole
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: WSHGSZJHGFBODT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1<br/>[FR] DÉRIVÉS SUBSTITUÉS DE PHTALAZIN-1(2H)-ONE COMME INHIBITEURS SÉLECTIFS DE LA POLY(ADP-RIBOSE) POLYMÉRASE-1
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2014102817A1

  公开（公告）日：2014-07-03

  The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis. The compounds of formula (I) are useful as PARP-1 inhibitors for the treatment of, e.g. cancer.

  本发明涉及一般式（I）的新化合物，它们的立体异构体、位置异构体、互变异构体以及其合成中所涉及的新中间体，它们的药学上可接受的盐、药学上可接受的溶剂合物以及含有它们的药物组合物。本发明还涉及一种制备一般式（I）的新化合物、它们的立体异构体、位置异构体、互变异构体、药学上可接受的盐、药学上可接受的溶剂合物、含有它们的药物组合物以及其合成中所涉及的新中间体的方法。一般式（I）的化合物可用作PARP-1抑制剂，用于治疗癌症等疾病。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2015097713A1

  公开（公告）日：2015-07-02

  The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及一种新颖的一般式（I）的GPR 40激动剂，其互变异构体、立体异构体、药用盐、含有它们的药物组合物、它们的制备方法、这些化合物在医学中的应用以及它们制备中涉及的中间体。
• 2-PHENYL-5-HETEROCYCLYL-TETRAHYDRO-2H-PYRAN-3-AMINE COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND ITS ASSOCIATED DISORDERS
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20150246025A1

  公开（公告）日：2015-09-03

  The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of diabetes mellitus (DM), obesity and other metabolic disorders. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.

  本发明涉及一种新颖的化合物，其通式为（I），其互变异构体形式，其对映异构体，其顺反异构体，其药学上可接受的盐或前药，用于治疗或预防糖尿病（DM），肥胖症和其他代谢性疾病。本发明还涉及制备所述化合物的方法，以及包含它们的药物组合物和它们的用途。
• NOVEL HETEROCYCLIC COMPOUNDS
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20160257701A1

  公开（公告）日：2016-09-08

  The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及一种新的GPR 40激动剂，其通式为（I），它们的互变异构体，立体异构体，药学上可接受的盐，包含它们的制药组合物，制备它们的方法，这些化合物在医学上的使用以及其制备中涉及的中间体。
• SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20150291603A1

  公开（公告）日：2015-10-15

  The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

  本发明涉及一种新的化合物通式(I)，其立体异构体、区域异构体、互变异构体和合成中所涉及的新中间体，其药学上可接受的盐、药学上可接受的溶剂和含有它们的药物组合物。本发明还涉及一种制备新的化合物通式(I)、其立体异构体、区域异构体、互变异构体、其药学上可接受的盐、药学上可接受的溶剂、含有它们的药物组合物和合成中所涉及的新中间体的方法。